Jasper Therapeutics Highlights Promising Briquilimab Data in Chronic Urticaria and Other Inflammatory Diseases in Latest Corporate Presentation
Reuters
Oct 14
<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Highlights Promising Briquilimab Data in Chronic Urticaria and Other Inflammatory Diseases in Latest Corporate Presentation
Jasper Therapeutics Inc. presented new data on briquilimab, its investigative drug for chronic urticaria, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The presentation highlighted rapid, deep, and durable efficacy, with mean UAS7 reductions greater than 25 points observed four weeks post-dose and up to a 92% complete response rate in certain cohorts. Safety and tolerability data from the BEACON and SPOTLIGHT studies showed that adverse events, mostly related to KIT blockade, were generally low grade and resolved with repeat dosing. Jasper Therapeutics also addressed ongoing investigations into confounded results from two BEACON study cohorts, noting that the issues were not related to the drug substance or product, and are conducting site and patient audits with additional data expected in late Q4 2025. Briquilimab is not approved for any indication at this time. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.